Impact of epoetin β on quality of life in patients with malignant disease

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 988-995

  Boogaerts, M ^a   Coiffier, B ^b   Kainz, C ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

Anaemia; Erythropoietin; Factors; Neoplasms; Predisposing; Quality of life; Recombinant

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LABORATORY TEST; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCALE UP; SCORING SYSTEM; SOLID TUMOR; STANDARDIZATION;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0038369006     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600801     Document Type: Article

References (37)

1. Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S (1994) Guidelines for the use of recombinant human erythropoietin. Haematologica 79: 526-533
2. Beguin Y, Yerna M, Loo M, Weber M, Fillet G (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82: 648-653
3. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91: 2214-2221
4. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058-1062
5. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801-806
6. Cazzola M, Beguin Y (1992) New tools for clinical evaluation of erythron function in man. Br J Haematol 80: 278-284
7. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
8. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81: 434-441
9. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (3 Suppl 2): 13-19
10. Cremieux P-Y, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16: 459-472
11. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5: 353-360
12. Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113: 172-179
13. Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, Perona G, De Laurenzi A, Torelli U, Ascari E, Rossi Ferrini PL, Caligaris-Cappio F, Pileri A, Resegotti L (1998) The effectiveness and tolerabllity of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28: 127-134
14. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412-3425
15. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-2882
16. Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34: 20-26
17. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218-1234
18. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Jospeh PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536
19. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634
20. Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21-28
21. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruicjshank DJ, Atkinson RJ, Soukop M, Rankin EM et al. (1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329-333
22. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874
23. Ludwig H (1999) Epoetin in cancer-related anaemia. Nephrol Dial Transplant 14: 85-92
24. Manegold C (1998) The causes and prognostic significance of low hemoglobin levels in tumour patients. Strahlenther Onkol 174 (Suppl IV): 17-19
25. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard E-M, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 9: 1109-1115
26. Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 (Suppl 1): S19-S28
27. Nunnaly JC (1978) Psychometric Theory, 2nd edn. New York, London: McGraw-Hill
28. Österborg A, Boogaerts MA, Cimino R, Essers V, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D for the European Study Group of erythropoietin (Epoetin Beta) treatment in multiple myeloma and non-Hodgkin's lymphoma (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicentre study. Blood 87: 2675-2682
29. Österborg A, Brandberg Y, Molostova V, Iosova G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin (epoetin beta) in hematological malignancies. J Clin Oncol 20: 2486-2494
30. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89: 831-837
31. Sheffield R, Sullivan SD, Saltiel E, Nishimura L (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15-22
32. Skillings JR, Sridhar FG, Wong C, Paddock L (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16: 22-25
33. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJM, Reed NS, Fairlamb DJ, Chan SYT, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174-182
34. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A (1995) Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33: AS264-AS279
35. Ware JE, Kosinski M, Keller SD (1994) Physical and Mental Health Summary Scales: a User's Manual. Boston MA: Health Assessment Lab
36. Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13: 1255-1264
37. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 13: 63-74